Table 3. Various clinical factors including TP53 mutation status and response to HMA therapy.
| Variables | Number | CR rate (%) | P value | OR rate (%) | P value |
|---|---|---|---|---|---|
| All patients | 168 | 49 (29) | NA | 57 (34) | NA |
| Age < 70 | 102 | 34 (33) | 0.14 | 39 (38) | 0.14 |
| Age ≥ 70 | 66 | 15 (23) | 18 (27) | ||
| MDS (including RAEB-T) | 139 | 40 (29) | 0.81 | 47 (34) | 0.95 |
| CMML | 29 | 9 (31) | 10 (35) | ||
| WHO classification | 0.14 | 0.06 | |||
| 5q- syndrome | 2 | 1 (50) | 1 (50) | ||
| RA | 16 | 3 (19) | 3 (19) | ||
| RCMD | 27 | 5 (19) | 5 (19) | ||
| RCMD-RS | 1 | 0 (0) | 0 (0) | ||
| RAEB-1 | 37 | 11 (30) | 14 (38) | ||
| RAEB-2 | 32 | 7 (22) | 9 (28) | ||
| RAEB-T | 19 | 10 (53) | 11 (58) | ||
| RARS | 3 | 2 (67) | 2 (67) | ||
| MDS-U | 1 | 0 (0) | 1 (100) | ||
| MDS/MPD | 1 | 1 (100) | 1 (100) | ||
| CMML-1 | 21 | 5 (24) | 6 (29) | ||
| CMML-2 | 8 | 4(50) | 4 (50) | ||
| Therapy-related MN | 128 | 38 (30) | 0.79 | 44 (34) | 0.83 |
| De novo disease | 40 | 11 (28) | 13 (33) | ||
| ANC ≥ 0.8 × 109/L | 109 | 26 (24) | 0.06 | 31 (28) | 0.06 |
| ANC < 0.8 × 109/L | 58 | 22 (38) | 25 (43) | ||
| HGB ≥ 8 g/dL | 148 | 44 (30) | 0.66 | 52 (35) | 0.37 |
| HGB < 8 g/dL | 20 | 5 (25) | 5 (25) | ||
| PLT ≥ 50 × 109/L | 102 | 35 (34) | 0.07 | 42 (41) | 0.01 |
| PLT < 50 × 109/L | 66 | 14 (21) | 15 (23) | ||
| BM blast ≤ 10% | 111 | 29 (26) | 0.17 | 33 (30) | 0.12 |
| BM blast > 10% | 55 | 20 (36) | 23 (42) | ||
| Cytogenetics | |||||
| Non complex | 114 | 34 (30) | 0.93 | 39 (34) | 0.88 |
| Complex | 48 | 14 (30) | 17 (35) | ||
| Non-monosmal | 119 | 34 (29) | 0.62 | 39 (33) | 0.42 |
| Monosomal | 43 | 14 (33) | 17 (40) | ||
| IPSS-R | |||||
| Very Low/Low/Int | 72 | 19 (26) | 0.60 | 23 (32) | 0.74 |
| High/Very high | 93 | 28 (30) | 32 (34) | ||
| Therapy types | |||||
| SOC Aza/DAC | 78 | 22 (28) | 0.88 | 25 (32) | 0.71 |
| HMA+investigational | 90 | 27 (30) | 32 (35) | ||
| TP53-mutated | 38 | 13 (34) | 0.38 | 15 (45) | 0.13 |
| TP53 WT | 130 | 35 (27) | 41 (32) |
Abbreviations. CR: complete response, OR: overall response, RA: refractory anemia, RCMD: refractory cytopenia with multilineage dysplasia, RCMD-RS: refractory cytopenia with multilineage dysplasia with ringed sideroblast, RAEB: refractory anemia with excess blast, RARS: refractory